Background and aims: The transcription factor nuclear factor kappa B (NF-kB)
The redox-sensitive transcription factor nuclear factor kappa B (NF-kB) displays pleiotropic effects during inflammation, immune response, cell survival and proliferation and is a major target of novel drugs counteracting the inflammatory response. 1 2 In the liver, however, NF-kB is thought to exhibit a dual role, depending on the cell type. Activation of NF-kB in the resident liver macrophages, ie, Kupffer cells (KCs), causes increased expression of proinflammatory cytokines leading to inflammation and liver failure. 3 Induction of NF-kB activity in hepatocytes, however, is linked to cellular protection by increasing the transcription of antiapoptotic genes. 4 Most studies addressing this point have been performed with isolated liver cells in vitro.
Recent publications tried to shed some light on this issue in vivo. [5] [6] [7] [8] Since constitutive NF-kB knock-out mice die during embryogenesis, 9 an approach guided by the creation of conditional knock-out animals was pursued. NF-kB is mainly activated upstream by a kinase complex containing the (catalytic) subunits I-kappaB kinase a (IKKa), IKKb and the regulatory protein NF-kB essential modulator (NEMO). 10 11 Hepatocyte-specific NEMO deletion leads to a complete inactivation of NF-kB, which correlates with enhanced susceptibility to tumour necrosis factor a (TNFa) stimulation, ischaemia-reperfusion injury 5 and, finally, to cancer development. 6 Hepatocyte-specific p65 knock-out mice are also more susceptible to TNFa-induced liver damage. 7 IKKb knock-out in hepatocytes does not abolish NF-kB activation entirely, hence a protection of the parenchyma to a certain degree upon TNFa challenge still remains. 8 To our knowledge, conditional NF-kB knock-out mice for KCs are not available, and a genetic approach to inhibit NF-kB in KCs would not easily be suitable for clinical application. Moreover, adenoviral transfection of an IkB super-repressor is not limited to KCs, 12 and liposomal targeting of the liver macrophages with NF-kB inhibiting decoy oligodeoxynucleotides cannot ensure an exclusive transport to KCs only. 13 Therefore, aims of this study were (1) to develop a non-genetic approach to selectively abrogate NFkB activation in KCs without interfering with NFkB activity in hepatocytes, and (2) to subsequently elucidate the role of NF-kB activation in KCs in different settings of hepatic inflammatory injury.
Here we report a novel Kupffer cell specific carrier based on gelatin nanoparticles (NPs), which enables selective delivery of NF-kB decoy oligodeoxynucleotides to KCs without affecting NF-kB in hepatocytes. NF-kB decoy oligodeoxynucleotides are double-stranded oligonucleotides which lead to competitive cis-trans interactions between oligonucleotides and the transcription factor, thus preventing binding of NF-kB to the designated DNA. 14 15 In a model of D-galactosamine/lipopolysaccharide (GalN/LPS)-induced as well as concanavalin A (ConA)-induced hepatic failure, treatment with NF-kB D-NPs reduced liver injury markedly. Interestingly, NF-kB activation in KCs seems to possess a different role in the setting of warm hepatic ischaemia-reperfusion injury, since here selective inhibition led to an increase of liver damage.
MATERIALS AND METHODS Decoy oligodeoxynucleotides
NF-kB decoy oligodeoxynucleotides (59-AGT TGA GGG GAC TTT CCC AGG C-39, 59-GCC TGG GAA AGT CCC CTC AAC T-39) and scrambled NF-kB decoy oligodeoxynucleotides (59-CCT TGT ACC ATT GTT AGC C-39, 59-GGC TAA CAA TGG TAC AAG G9) have been described elsewhere 16 17 and were purchased from Biomers, Ulm, Germany (biomers.net). Consensus sequences for p50 and p65 are underlined. For improved stability, all oligodeoxynucleotides were bridged with a phosphorothioate (PTO) backbone. 18 For biodistribution studies, cis-decoy oligodeoxynucleotides were 59-end-labelled with Alexa Fluor 488 fluorescent dye.
Preparation of oligonucleotide-loaded gelatin nanoparticles
Gelatin NPs were prepared as described previously by Zillies and Coester. 19 NPs were incubated with a solution containing NF-kB decoy ODN, scrambled decoy ODN or Alexa Fluor 488-labelled NF-kB decoy ODN respectively. D-NP suspensions were freezedried and finally rehydrated under iso-osmotic conditions.
Animals
Male Sprague-Dawley rats (190-220 g) were purchased from Charles River laboratories (Sulzfeld, Germany). C57Bl/6 mice (20-25 g) were obtained from the animal facilities of the Institute of Experimental and Clinical Pharmacology and Toxicology of the University of Erlangen-Nuremberg, Germany. They were maintained under controlled conditions (22uC, 55% humidity and 12 h day/night rhythm) and fed a standard laboratory chow.
Experimental model for distribution studies in rats
One millilitre of buffered NP solution containing 20 nmol Alexa Fluor 488 59-end-labelled NF-kB decoy oligonucleotides was injected into the portal vein and the organs were removed after 15 min. Livers were drained, rinsed free of blood with PBS and perfused with formalin 3% in PBS for protein fixation.
Experimental model of NF-kB induction by LPS in rats
One millilitre of either 20 nmol NF-kB D-NP solution or scrambled D-NP solution was injected into the portal vein. After 15 min, 10 mg of LPS (50 mg/ml in PBS, Escherichia coli serotype 055:B05; Sigma, Munich, Germany) was applied to the portal vein. After 30 min blood and organs were collected.
Mice model of fulminant hepatic failure
GalN (Roth, Karlsruhe, Germany) was administered i.p. at 700 mg/kg 30 min prior to lipopolysaccharide (LPS, Salmonella abortus equi, i.p., 4.5 mg/kg; Sigma-Aldrich Chemie, Taufkirchen, Germany). 20 ConA (Sigma-Aldrich Chemie) was applied intravenously at 20 mg/kg. Mice were treated (i.v.) with 150 ml of a 3 nmol NF-kB D-NPs or scrambled D-NPs per mouse 20 min prior to GalN administration or 2 h prior to ConA administration. In another set of experiments NF-kB NPs or scrambled D-NPs were given 2 h after GalN/LPS injection. Twenty animals per group were used to determine survival rate.
Rat model of partial warm hepatic ischaemia-reperfusion injury
The model used has been described by us before. 21 The arterial and portal blood flow to the left lateral and median lobe of the liver was interrupted by applying an atraumatic clip, resulting in a 70% liver ischaemia. After 1 h of ischaemia, the blood supply was restored by removal of the clip and the reperfusion period was initiated. Blood samples were collected into heparinised tubes and animals were sacrificed after 2 and 24 h of reperfusion, respectively.
Fifteen minutes prior to initiation of ischaemia, 1.0 ml of either 20 nmol NF-kB D-NP solution or scrambled D-NP solution, respectively, were injected into the portal vein over a period of 5 min.
Histology of rat liver tissue
Formalin-fixed, paraffin embedded rat liver samples were cut into 8 mm slices. After deparaffinisation/rehydration, slices were stained using Coverplate chambers (Thermo Shandon, Frankfurt, Germany). For evaluation of NF-kB activation, sections were incubated with a rabbit polyclonal p65-antibody (1:50; RB-9034; Labvision, Fremont, California, USA) and a mouse anti-rat monoclonal CD 163-antibody (1:100; MCA342R; AbD Serotec, Duesseldorf, Germany) overnight at 4uC. The secondary antibodies Alexa Fluor 488 goat-anti-mouse and Alexa Fluor 546 goat-anti-rabbit (Invitrogen, Karlsruhe, Germany) were applied for 45 min, followed by staining of nuclei with Hoechst. Sections were mounted with PermaFluor Mounting Medium (Beckmann Coulter, Krefeld, Germany) and analysed by confocal laser scanning microscopy (CLSM) (Zeiss LSM 510 Meta CLSM; Carl Zeiss Microscope Systems, Jena, Germany). For evaluation of nanoparticle biodistribution, slices were treated accordingly (primary antibody mouse-anti-rat monoclonal CD 163, AbD Serotec, and secondary antibody Alexa Fluor 633 goat-anti-mouse, Invitrogen).
For evaluation of effects of decoy-nanoparticles on tissue damage, leucocyte infiltration and apoptosis after ischaemiareperfusion, formalin-fixed liver tissue samples were embedded in paraffin. Sections (5 mm thickness) were cut and stained with haematoxylin and eosin (HE) using a standard protocol, with the terminal desoxynucleotide transferase-mediated dUTP nick end labelling (TUNEL) assay according to the manufacturer's instructions (ApopTag Peroxidase In Situ Apoptosis Detection Kit; Intergen, Purchase, New York, USA) and with naphthol ASD chloroacetate (ASD) in order to stain granulocytes.
The histological evaluations were done in a blinded fashion and a Leitz Laborlux S microscope (Leica Microsystems, Wetzlar, Germany) was used. In HE-stained sections the extent of necrosis (comprising loss of architecture, karyolysis and cell swelling) was expressed as a percentage. The number of ASDstained granulocytes in the periphery of the necrosis was counted in 10 high-power fields (HPFs). Apoptotic hepatocytes were counted in 20 HPFs and were identified by staining with the TUNEL assay in combination with morphological features as chromatin condensation, forming of apoptotic bodies and cell shrinkage.
DNA binding of NF-kB
Electromobility shift assays (EMSAs) were performed as described previously. 22 The consensus binding-sequence for NF-kB was 59-AGT TGA GGG GAC TTT CCC AGG C-39 (Promega, Mannheim, Germany). Relative light unit (RLU) density was determined by autoradiography using the Cyclone Phosphor Imager (Perkin Elmer, Dreieich, Germany).
Analysis of TNFa mRNA expression
mRNA from liver tissue (25 mg) was isolated using the RNEasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was carried out using the High Capacity cDNA Reverse Transcription Kit. Real time PCR was conducted with the TaqMan Universal Master Mix Kit in a 7300 Real-Time PCR System (all from Applied Biosystems, Hamburg, Germany).
TNFa primers and probe (Rn99999017_m1) were also obtained from Applied Biosystems. Glyceraldehyde-3-phosphate dehydrogenase GAPDH) primers were designed using the Primer Express 2.0 software program. GAPDH forward primer: 59-GGG AAG GTG AAG GTC GGA GT-39; reverse primer: 59-TCC ACT TTA CCA GAG TTA AAA GCA G-39; probe: 59-ACC AGG CGC CCA ATA CGA CCA A-39.
Results were quantified based on the relative expression of the TNFa gene versus the housekeeping gene GAPDH using the mathematical model for relative quantification according to Pfaffl. 23 
Measurement of transaminase activities
Activities of serum aminotransferases (ALT and AST) were determined in heparinised serum 7 h after the induction of liver injury using an automated procedure.
Haematoxylin-eosin staining of mice liver tissue
Morphology of formalin-fixed, paraffin-embedded samples of the mice liver tissues was evaluated after H&E-staining (30 s Mayer's Haemalum (Merck, Darmstadt, Germany); 3 s DEPCtreated water; 1 min 70% ethanol; 1 min 95% ethanol; 30 s eosin Y (Sigma Chemical, Deisenhofen, Germany); 1 min 95% ethanol; 1 min 95% ethanol; 1 min 100% ethanol; air-dry for at least 10 min).
Cytokine measurement in murine plasma
Sandwich ELISAs for murine plasma TNFa and IL6 were performed using flat-bottom high-binding polysterene microtitre plates (Greiner, Nurtingen, Germany). Antibodies were purchased from BD PharMingen Transduction Laboratories (Heidelberg, Germany). Streptavidin-peroxidase (Jackson Immuno Research, West Grove, Pennsylvania, USA) and the peroxidase chromogen tetramethylbenzidine (Boehringer Mannheim, Mannheim, Germany) were used according to the manufacturers' instructions.
Cytokine measurement in rat plasma
Blood samples were taken after 24 h of post-ischaemic reperfusion, heparinised and analysed with a Rat TNFa UltraSensitive ELISA Kit (BioSoure, Camarillo, California, USA).
Western blot analysis
Western blot analysis were performed as described previously. 22 Proteins transferred to the membrane were identified by incubating with primary antibody (Bcl-xl; Santa Cruz, Heidelberg, Germany; XIAP, JNK, pJNK, Cell Signaling, Frankfurt, Germany; at 4uC, over night), followed by incubation with a HRP-conjugated secondary antibody (goat anti rabbit, Dianova, Hamburg, Germany). The reactive bands have been visualised employing a chemiluminescent detection kit (ECL Plus, Amersham Pharmacia, Uppsala, Sweden). b-Actin was used as loading control (Millipore, Billerica, Massachusetts, USA).
Measurement of caspase-3 like activity
Liver tissue (20-60 mg) was homogenised (Potter S, B. Braun Biotech) in 200-600 ml lysis buffer (25 mmol/l Hepes; 5 mmol/l MgCl 2 ; 1 mmol/l EGTA; pH 7.5). Protein quantification was done by use of the Bradford assay. 24 Extracts were incubated with Ac-DEVD-AFC, and the generation of AFC was determined by fluorescence measurement (excitation: 385 nm; emission: 505 nm). 
Statistical analysis
Animal experiments were performed using the number of animals as shown in the respective figure legends. Results are shown as mean with the SEM. Statistical analysis was performed using the GraphPad Prism 3.03 software. Significance (*) was calculated at a 95% confidence interval in comparison to the corresponding control experiments (nonparametic t test).
RESULTS

Persistent binding of NF-kB decoy oligonucleotides onto gelatin nanoparticles of well-defined size diameter
Oligonucleotides (ODNs) were bound to gelatin NPs via ionic interactions between the negatively charged DNA and the positively modified surface of the NP. 19 25 A supernatant of decoy oligonucleotide-loaded gelatin NPs (D-NPs) suspension was analysed spectrophotometrically after various times to ensure persistent attachment of NF-kB decoy oligonucleotides. D-NPs displayed an average size of 262.5 nm with a polydispersity index of 0.105, which indicates the homogenous size distribution of particles. 19 25 Intraportal injection of NF-kB gelatin nanoparticles results in predominant uptake by hepatic Kupffer cells Upon intravenous administration, NPs are generally cleared from the circulation through phagocytosis, preferentially by macrophages of the reticuloendothelial system (RES) concentrating mainly in liver and spleen. 26 Due to their well-defined particle size distribution around 260 nm, solid, inflexible gelatin NPs are too large to pass through the endothelial fenestrae (approx. 175 nm wide). Therefore, the uptake of gelatin NPs by hepatocytes should be almost impossible since the parenchyma is not accessible to these constructs.
Fifteen minutes after application of gelatin NPs loaded with Alexa Fluor 488-labelled decoy oligonucleotides, the majority of decoy oligonucleotides were distributed within the liver referring to the number of positively stained cells. No detectable fluorescence was found in the brain, the kidney or the heart, and smaller quantities could be seen in lung and spleen ( fig 1A) . Figure 1B displays the exact pattern of hepatic allocation, with a distinguished uptake of decoy oligonucleotides by KCs. Importantly, hepatocytes showed no incorporation of decoy oligonucleotides.
NF-kB decoy oligonucleotide-loaded gelatin nanoparticles reduce NF-kB activation and translocation in Kupffer cells
EMSA analysis (fig 2A) To confirm that our D-NPs in fact inhibit NF-kB driven transcription, we measured the expression of the TNFa gene. D-NP markedly attenuated TNFa expression, whereas scrambled D-NPs had no effect (51.45 (SD 20.23) vs 81.52 (SD 21.09) x-fold increase, ie, reduction to 63.1%; fig 2D) . The discrepancy between the extent of NF-kB inhibition and TNFa reduction might reflect the fact that TNFa underlies additional regulatory mechanisms besides the NF-kB system.
GalN/LPS-induced liver injury is reduced by NF-kB oligonucleotide-loaded gelatin nanoparticles
The effect of D-NPs was tested in a widely accepted model of fulminant hepatitis ie, in the model of GalN/LPS induced liver injury. NF-kB D-NPs were injected 20 min before GalN/LPS challenge. Liver injury was strongly reduced as determined by measurement of serum transaminase activities 7 h after GalN/ LPS administration ( fig 3A) . The fact that serum transaminase activities in NF-kB D-NP-treated animals after GalN/LPS administration are within the range of those of control animals suggests a lack of adverse effects of D-NPs to the liver.
Histological examination of liver tissue by H&E staining revealed a complete preservation in liver structure of NF-kB D-NP-treated animals ( fig 3B) . Furthermore, survival of animals was significantly increased by treatment with NF-kB D-NPs, scored 7 h after GalN/LPS challenge. Only one animal died in the D-NP-treated group (n = 20) compared to eight animals in the group that received scrambled D-NPs (n = 20) prior to GalN/LPS stimulation (p,0.05).
Interestingly, injection of NF-kB D-NPs even 2 h after the GalN/LPS administration seems to be beneficial with regard to transaminase measurements. Alanine aminotransferase (ALT) levels are significantly reduced in animals treated with NF-kB D-NPs as compared to the scrambled D-NP (1230 (SD 136) vs 3110 (SD 880) U/l) whereas aspartate transaminase (AST) levels only show a tendency of reduction in the NF-kB D-NP group as compared to the scrambled D-NP group (1306 (SD 242) vs 1790 (SD 216) U/l).
As liver injury was diminished by NF-kB D-NPs, we next evaluated the degree of NF-kB inhibition and subsequent NF-kB dependent transcription. EMSA analysis clearly showed a Figure 5 Role of the administration of nuclear factor kappa B (NF-kB) oligonucleotide-loaded gelatin nanoparticles (D-NPs) in liver injury after challenge with concanavalin A (ConA). Plasma levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) of mice subjected to 7 h of ConA challenge (n = 3, mean with the SEM, *p,0.05 vs scramble D-NPs).
significant reduction in NF-kB binding activity (4.48 (SD 1.13) vs 10.15 (SD 0.12) x-fold increase, ie, reduction to 44.1%; fig 3C) . The TNFa concentration in plasma was decreased and a pronounced reduction of interleukin 6 (IL6) plasma concentration was observed in animals, which had received NF-kB D-NPs ( fig 3D) .
Oligonucleotide-loaded gelatin nanoparticles attenuate proapoptotic liver signalling
The jun N-terminal kinase (JNK) plays a major role in the initiation of apoptotic pathways. Cross-talk between JNK and NF-kB has been postulated before. 27 Most strikingly, inhibition of NF-kB in KCs led to a reduction in JNK phosphorylation ( fig 4A) . In contrast, anti-apoptotic proteins such as X-linked inhibitor of apoptosis protein (XIAP) or Bcl-xl remained unchanged or even increased, respectively, as shown in fig 4B. In line with these effects caspase-3 activity in liver tissue was markedly decreased (fig 4C) .
NF-kB oligonucleotide-loaded gelatin nanoparticles reduce injury in the concanavalin a model of hepatitis
For LPS challenge circulating TNFa is relevant, 28 we therefore investigated the effects of D-NPs also in the ConA induced liver 11 (1) 12 (2) Data are mean (SEM).
damage which is mainly mediated by cell-bound TNFa. Interestingly NF-kB D-NPs abrogated ConA-induced liver damage as well ( fig 5) .
Impact of NF-kB oligonucleotide-loaded gelatin nanoparticles on hepatic ischaemia-reperfusion injury
Hepatic ischaemia occurs during liver resections or transplantations. It is assumed that NF-kB is activated in KCs soon upon reperfusion. As yet the actual role of NF-kB in KCs in ischaemia-reperfusion injury has not been addressed due to the lack of a suitable experimental tool. Hence, we investigated the impact of Kupffer cell targeted NF-kB for the outcome of hepatic ischaemia-reperfusion injury by injecting D-NPs. Interestingly, an inhibition of NF-kB binding activity ( fig 6A) led to an increase in liver injury after 24 h of reperfusion ( fig 6B) . Measurement of plasma TNFa indicated no difference in TNFa levels between the respective groups at 24 h reperfusion time ( fig 6C) . Furthermore, histological analysis as described under ''materials and methods'' revealed that ischaemia-reperfusion liver tissue of NF-kB D-NP-treated animals display a higher proportion of centrilobular coagulative necrosis, as well as stronger leucocyte infiltration, but no difference in TUNELpositive, apoptotic cells ( 
DISCUSSION
KCs play an important role in the pathogenesis of various inflammatory liver diseases. 29 Inhibition of Kupffer cell activity by depletion with gadolinium chloride or clodronate liposomes reduces liver damage after ischaemia/reperfusion and ConA treatment, respectively. [30] [31] [32] However, complete elimination and permanent inactivation of this important cell type from the liver is not a therapeutic option, since KCs are indispensable for immune function. 33 Thus, strategies aiming at a reversible inhibition of KC-driven inflammatory signalling such as NF-kB activation which might be clinically applicable are an important goal. Here we present a novel approach of selective KC targeting, which (1) might be of potential clinical use and (2) was appropriate to elucidate the role of NF-kB in KCs in various types of acute liver injury and ischaemiareperfusion injury.
In a model of fulminant liver failure (GalN/LPS), a disease that is associated with many complications and high mortality in the clinic, administration of KC-targeting NF-kB D-NPs indeed resulted in a marked reduction of liver injury. Hepatocyte-specific NF-kB inhibition is associated with a TNFa induced increase of apoptosis and mortality. 5 7 Kupffer cell selective downregulation of NF-kB by D-NPs, as shown here, leads to decreased inflammatory cytokine release as well as reduced apoptotic activity and tissue damage after GalN/LPS challenge. Along this line, phosphorylation and consecutively activation of the pro-apoptotic kinase JNK was blocked. This is in contrast to reports of NF-kB inhibition leading to prolonged JNK activation. 4 27 However, it has to be noted that these observations were made in hepatocytes. Obviously a selective inhibition of NF-kB in KCs leads to a reduction of parenchymal tissue injury in the liver, since the attenuation of TNFa production by KCs is most likely associated with lower JNK activity in hepatocytes and thus apoptotic activity as determined by caspase-3 activity. Selective inhibition of NF-kB in KCs did not impair XIAP expression, and even increased antiapoptotic Bcl-xl protein levels, both driven by NF-kB activity, furthermore pointing to the fact that hepatocyte signalling was not immediately affected by D-NPs. In contrast, anti-apoptotic signalling in hepatocyte-specific NF-kB deficient mice presented by Beraza et al 5 and Geisler et al. 7 is reduced, which might explain the worsening of liver injury in their models.
Recent data 34 show a marked increase in liver damage after GalN/LPS challenge, if NF-kB activity is reduced by the general NF-kB inhibitor pyrrolidene dithiocarbamate (PDTC), which blocks NF-kB activation in both KCs and hepatocytes.
Hepatic ischaemia/reperfusion injury is another setting where inflammatory processes are thought to be responsible for tissue damage. KCs react fast after the onset of the reperfusion period and produce large amounts of reactive oxygen species (ROS), which subsequently trigger production and release of NF-kB driven cytokines like TNFa and IL6. 35 Thus, a selective NF-kB inhibition in KCs should result in a similar beneficial outcome as seen in the model of GalN/LPS induced liver injury. For instance, Lentsch and colleagues showed recently that higher NF-kB levels in hepatocytes during ischaemia-reperfusion are linked with protection, while an increase of NF-kB in KCs rather induces TNFa release and liver damage.
36 Surprisingly, application of D-NPs and thus Kupffer cell specific NF-kB inhibition increased hepatic damage even further. This is in contrast to Matsui et al, who described less liver injury by treatment with PDTC in a model of 1 h warm ischaemia and 24 h of reperfusion. 37 This again supports the notion that an overall inhibition of NF-kB with PDTC, in comparison to a selective NF-kB blockade in KCs, leads to opposite effects. Moreover, PDTC acts as a radical scavenger and exerts mainly antioxidative properties, 38 which makes its use as selective NF-kB inhibitor rather questionable.
In conclusion, we here present a novel tool to selectively inhibit NF-kB in KCs in vivo. We examined the impact of this selective NF-kB inhibition in the inflammatory models of GalN/LPS and ConA challenge, respectively, as well as in hepatic ischaemiareperfusion injury. It turned out that NF-kB in KCs seems to be indispensable for the protection of the hepatic parenchyma after ischaemia-reperfusion, while a selective inhibition in KCs after GalN/LPS or ConA challenge results in protection of the liver. Interestingly, the inflammatory impact caused by Kupffer celldependent NF-kB-activation during ischaemia-reperfusion seems not to be predominant for tissue injury. In contrast, selective inhibition in KCs leads to an increase in hepatic injury. Therefore, treatments aiming at NF-kB in the liver have to be used carefully, as effects specific to the type of cell and to the type of injury have to be taken into account.
